查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1931242

植入式避孕释放装置市场按产品类型、药物类型、最终用户、通路、聚合物材料和时间段划分，全球预测（2026-2032年）

Implantable Contraceptive Drug Eluting Devices Market by Product Type, Drug Type, End User, Distribution Channel, Polymer Material, Duration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年植入式避孕药释放装置市场规模为 4.8321 亿美元，预计到 2026 年将成长至 5.0852 亿美元，到 2032 年将达到 7.0505 亿美元，复合年增长率为 5.54%。

关键市场统计数据
基准年 2025 4.8321亿美元
预计年份：2026年 5.0852亿美元
预测年份 2032 7.0505亿美元
复合年增长率 (%) 5.54%

对植入式避孕装置生态系统的全面概述：重点关注技术进步、临床重点和系统层面的应用趋势

植入式避孕释放装置领域独特地融合了生物医学工程、生殖健康政策和长期避孕策略。这些装置结合了聚合物科学和控释药物技术，能够持续、长期地释放激素，为重复给药或每日用药提供了替代方案。临床医生和计画负责人重视这些植入在提高用药依从性、减少意外怀孕以及提供可预测的避孕效果和最大限度减少后续临床接触方面的潜力。

材料科学的突破、设备配置的创新以及政策重点的转变，正在如何重塑临床应用与竞争优势

由于技术、监管和社会因素的共同作用，植入式避孕器材领域正经历着变革性的转变。可生物降解和不可生物降解聚合物化学的进步正在拓展设计选择，有望实现更精确的药物释放曲线和更简单的取出程序。因此，产品开发团队越来越重视那些兼具可预测药物释放、生物相容性和易于生产的材料，这正在改变供应商关係和品管要求。

评估2025年关税调整对植入式避孕器材相关人员的供应链、筹资策略和商业化时程的影响

2025 年美国关税环境对从事植入式避孕器材设计、製造和分销的公司提出了独特的营运和策略考量。影响原料聚合物进口、活性药物成分运输和医疗设备组件的关税正在推高投入成本，并使供应商选择更加复杂，促使製造商重新评估其国内和国际采购策略。为此，一些公司正在加速关键供应链的在地化或寻找替代供应商以降低风险，而有些公司则透过利润管理和向下游买家调整价格来承担额外成本。

详细的細項分析重点阐述了产品设计、药物选择、临床试验中心、分销模式和材料选择对研发和上市策略的影响。

细分市场分析揭示了产品结构、活性成分、临床应用、通路、材料选择和持续时间等方面的细微需求驱动因素和开发重点。依产品类型划分，研究检视了多棒和单棒两种。在优先考虑易于插入和简化库存管理的场合，单棒结构更受欢迎；而对于寻求模组化给药柔软性和明确释放动力学的临床医生而言，多棒设计仍然是首选。按药物类型划分，研究检视了依托孕烯和levonorgestrel烯，二者在临床耐受性和药物动力学方面存在差异，这些差异会影响标籤策略和患者咨询需求。

区域比较分析阐明了法规结构、医疗服务模式和公共卫生优先事项对重点区域医疗器材普及率的影响

区域趋势表明，监管方式、服务提供模式和专案优先事项存在显着差异，这些差异影响着产品的推广路径。美洲市场往往优先考虑健全的上市后监测框架和以支付主导的价值验证，这鼓励製造商产生真实世界性能数据和卫生经济学分析，以支持报销谈判和大规模采购项目。在这些地区，临床网络和公私合营也促成了多样化的分销策略，这些策略将医院采购和零售药房管道与透过计划生育诊所开展的定向推广相结合。

策略竞争情报阐述了研发平台、伙伴关係、供应链韧性和证据生成如何决定长期市场领导地位。

植入式避孕器材领域的竞争动态并非主要取决于单一产品属性，而是更取决于涵盖研发深度、生产一致性、监管灵活性和商业性可行性的综合能力。主要企业正投资于平台技术，以期在通用工程基础上开发聚合物和配方变体，从而缩短开发週期并提升安全性。这些投资通常与先进的分析能力相结合，以支持严格的放行模型和批次间品质保证，这对于获得监管部门核准和临床医生的信任至关重要。

为製造商和专案负责人提供清晰、可操作的指南，以透过材料创新、真实世界数据和稳健的商业模式加速材料应用。

产业领导者应优先致力于减少临床、监管和商业化过程中的阻力。首先，投资于材料科学和配方优化，简化植入和取出流程，将有助于提高临床医生的接受度和患者的接受度。将产品特性与明确的临床差异化（例如减少副作用和简化追踪）相匹配，将有助于製造商缩短产品推广週期。

一个用于得出实用结论的系统性研究框架：一种结合了对医疗保健专业人员的访谈、技术文献综合和基于情境的供应链分析的方法。

本执行摘要的研究途径结合了多方面的证据基础和系统的分析方法，以得出可靠的实用结论。主要定性资料是透过对临床医生、供应链经理、监管专家和专案负责人的深入访谈获得的，旨在深入了解临床工作流程、植入和取出操作以及采购方面的考虑。这些实践者的见解与监管指导文件和已发表的临床文献进行了交叉比对，并用于检验各种器械配置的安全性、耐受性和性能特征。

综合考虑技术、监管和营运趋势，以支持持续的临床应用和对医疗保健系统产生影响所需的综合优先事项。

植入式避孕药释放装置的演变受到技术进步、政策环境变化和营运压力的共同影响，这些因素共同重塑了开发商、製造商和医疗服务提供者的战略重点。材料和配方创新赋予了装置新的特性，而监管环境和支付方的期望则推动了对真实世界数据和卫生经济学证据的需求。同时，贸易政策和供应链的考量也促使各组织重新评估筹资策略和营运韧性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型植入式避孕释放装置市场

  • 多桿
  • 单桿

第九章 依药物类型植入式避孕释放装置市场

  • 依托孕烯
  • levonorgestrel

第十章 依最终用户分類的植入式避孕释放装置市场

  • 诊所
    • 私人诊所
    • 公共诊所
  • 计划生育中心
  • 医院

第十一章植入式避孕释放装置市场（依通路划分）

  • 离线
  • 在线的

第十二章 依聚合物材料植入式避孕释放装置市场

  • 可生物降解
  • 不可生物降解

第十三章 依週期分類的植入式避孕药释放装置市场

  • 5年
  • 3年

第十四章植入式避孕药释放装置市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章植入式避孕药释放装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国植入式避孕释放装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国植入式避孕药释放装置市场

18. 中国：植入式避孕药释放装置市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3Daughters, Inc.
  • AbbVie Inc.
  • Allergan, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Celanese Corporation
  • Dare Bioscience, Inc.
  • DKT International
  • Femasys, Inc.
  • Gedeon Richter Plc.
  • Johnson & Johnson Services, Inc.
  • Lubrizol Life Science, Inc.
  • Medicines360
  • Medtronic plc
  • Mithra Pharmaceuticals SA
  • OCON Medical, Inc.
  • Organon & Co.
  • Pregna International Ltd.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • The Cooper Companies, Inc.
Product Code: MRR-7B550E008DDE

The Implantable Contraceptive Drug Eluting Devices Market was valued at USD 483.21 million in 2025 and is projected to grow to USD 508.52 million in 2026, with a CAGR of 5.54%, reaching USD 705.05 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 483.21 million
Estimated Year [2026] USD 508.52 million
Forecast Year [2032] USD 705.05 million
CAGR (%) 5.54%

An integrated overview of the implantable contraceptive drug-eluting device ecosystem highlighting technological advances, clinical priorities, and system-level adoption dynamics

The implantable contraceptive drug-eluting device sector occupies a distinct intersection of biomedical engineering, reproductive health policy, and long-term contraceptive access strategies. These devices combine polymer science and controlled drug release to deliver hormonal agents over extended durations, providing an alternative to repeat dosing regimens and daily administration methods. Clinicians and program planners value these implants for their potential to improve adherence, reduce unintended pregnancies, and deliver predictable contraceptive effects with minimal ongoing clinical contact.

Recent advancements in polymer matrices, delivery interfaces and minimally invasive insertion techniques have sharpened the clinical value proposition of these devices. In parallel, evolving regulatory pathways and enhanced post-market surveillance frameworks are increasing the emphasis on real-world performance and device lifecycle management. As a result, stakeholders from device designers to healthcare payers are recalibrating product requirements to prioritise long-term safety, ease of insertion and removal, and clear clinical guidance for diverse patient populations.

Transitioning from innovation to adoption requires multidisciplinary collaboration across R&D, manufacturing scale-up, clinician training and health system integration. Understanding the technical, regulatory and operational levers that influence adoption is essential for strategic planning. This introduction frames the broader dynamics that shape research, investment and commercialization decisions across the implantable contraceptive device landscape, emphasizing the need for actionable intelligence at each stage of development.

How material science breakthroughs, device configuration innovations and evolving policy priorities are reshaping clinical adoption and competitive differentiation in the field

The landscape for implantable contraceptive devices is undergoing transformative shifts driven by converging technological, regulatory and social forces. Advances in biodegradable and non-biodegradable polymer chemistries are expanding design options, enabling more precise elution profiles and potentially simplifying removal procedures. As a result, product teams are increasingly prioritizing materials that balance predictable drug release with biocompatibility and ease of manufacturing, which in turn alters supplier relationships and quality control expectations.

Clinically, there is a clear momentum toward devices that minimize procedural complexity while maximizing patient convenience and autonomy. Innovations in single-rod and multi-rod configurations are responding to varied clinical scenarios and patient preferences, and refinement of insertion tools is reducing provider learning curves. Concurrently, drug selection trends are shaped by therapeutic profiles such as etonogestrel and levonorgestrel, with developers optimizing formulations to match desired duration and side-effect profiles.

Health systems and payers are also reshaping the environment by emphasizing long-term outcomes and cost-effective care pathways. This is prompting manufacturers to invest in post-market evidence generation and health economics analyses to demonstrate value. Globally, shifting reproductive health policies and greater emphasis on access equity are creating new deployment models, from clinic-based programs to digital-supported service pathways. Together, these forces are driving a redefinition of competitive advantage that prizes integrated clinical support, robust safety data and adaptable distribution strategies.

Evaluating how 2025 tariff adjustments affect supply chains, sourcing strategies and commercialization timelines for implantable contraceptive device stakeholders

The United States tariff environment in 2025 introduces a distinct set of operational and strategic considerations for companies involved in the design, manufacture and distribution of implantable contraceptive devices. Tariffs that affect raw polymer imports, pharmaceutical active ingredient shipments and medical device components can increase input costs and complicate supplier selection, prompting manufacturers to reassess onshore versus offshore sourcing strategies. In response, some organisations accelerate efforts to localize critical supply chains and qualify alternate vendors to mitigate exposure, while others absorb incremental costs through margin management or price adjustments for downstream purchasers.

Beyond direct cost implications, tariffs influence capital allocation decisions for manufacturing investments. Where tariff pressures are persistent, firms may defer expansion of offshore production capacity and instead prioritize investments in automation and higher-yield processes within tariff-neutral jurisdictions. This rebalancing can alter the cadence of product launches and affect lead times for clinical trial device supply, which in turn impacts commercialization timelines.

Tariffs also intersect with regulatory compliance and logistics complexity. Shifts in cross-border cash flows and customs procedures can lengthen supply lead times and increase inventory holding requirements, which raises the importance of robust demand planning and supplier risk monitoring. Finally, tariff-driven cost dynamics have downstream consequences for access programs and procurement in public health settings, where tighter budgets may constrain adoption unless manufacturers deploy targeted pricing strategies or partnership models to preserve affordability and maintain programmatic uptake.

In-depth segmentation perspectives revealing how product design, drug selection, care settings, distribution models and material choices shape development and adoption strategies

Segmentation insights reveal nuanced demand drivers and development priorities across product architectures, active agents, care settings, distribution channels, material choices and duration profiles. Based on Product Type, the market is studied across Multi Rod and Single Rod, with single-rod architectures gaining preference where ease of insertion and reduced inventory complexity are prioritized, while multi-rod designs remain relevant for clinicians seeking modular dosing flexibility and distinct release kinetics. Based on Drug Type, the market is studied across Etonogestrel and Levonorgestrel, each presenting differentiated clinical tolerability and pharmacokinetic considerations that influence labeling strategies and patient counselling needs.

Based on End User, the market is studied across Clinics, Family Planning Centers, and Hospitals, and Clinics are further studied across Private Clinics and Public Clinics, which underscores the importance of tailored training and reimbursement approaches: private clinics may prioritise patient experience and premium service bundles, while public clinics and family planning centers emphasise cost-efficiency, task-shifting and high-throughput insertion programs. Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and the Retail Pharmacy channel is further studied across Chain Pharmacy and Independent Pharmacy, highlighting divergent fulfillment capabilities and provider engagement strategies that influence product visibility and point-of-care stocking decisions.

Based on Polymer Material, the market is studied across Biodegradable and Non-Biodegradable options, which shapes regulatory pathways and lifecycle management practices, as biodegradable systems can reduce the need for removal procedures but require robust characterization of degradation kinetics. Based on Duration, the market is studied across Five Year and Three Year modalities, with duration choices informing clinical positioning, payer dialogue and patient adherence messaging. These segmentation lenses collectively illuminate where clinical demands, logistical constraints and regulatory considerations intersect, informing prioritisation of development investments and commercialization focus areas.

Comparative regional intelligence explaining how regulatory frameworks, healthcare delivery models and public health priorities influence device uptake across major global regions

Regional dynamics exhibit clear differences in regulatory approaches, service delivery models and programmatic priorities that shape adoption pathways. Americas markets tend to prioritize robust post-market surveillance frameworks and payer-driven evidence of value, which encourages manufacturers to generate real-world performance data and health economic analyses to support reimbursement conversations and large-scale procurement programs. Clinical networks and private-public partnerships in these settings also enable diverse distribution strategies that combine hospital procurement and retail pharmacy access with targeted outreach through family planning clinics.

Europe, Middle East & Africa encompasses a range of regulatory maturity and healthcare delivery infrastructures, which requires adaptable market entry strategies. In higher-regulation European markets, conformity with stringent device and medicinal product interfaces is essential, as is alignment with national formularies and hospital procurement processes. In parts of the Middle East & Africa region, there is heightened emphasis on expanding access and integrating implants into public health programs, which elevates the importance of price-sensitive models, capacity building for provider training, and partnerships with governmental and non-governmental organisations to support scale-up.

Asia-Pacific demonstrates a mix of advanced manufacturing capabilities and rapidly evolving clinical adoption. Markets within this region favour scalable production options and increasingly sophisticated regulatory pathways that demand local clinical evidence and robust quality systems. Public health initiatives and growing private sector delivery networks create opportunities for multi-channel distribution, while demographic trends and policy commitments to reproductive health are strengthening long-term demand considerations. Across all regions, alignment of clinical training, supply chain resilience and payer engagement remains central to successful adoption.

Strategic competitive intelligence outlining how R&D platforms, partnerships, supply chain resilience and evidence generation determine long-term market leadership

Competitive dynamics in the implantable contraceptive device arena are shaped less by one-off product features and more by integrated capability sets that encompass R&D depth, manufacturing consistency, regulatory agility and commercial execution. Leading organisations are investing in platform technologies that allow polymer and formulation variations to be developed from a common engineering base, shortening development cycles and improving comparative safety profiling. These investments are frequently coupled with advanced analytical capabilities that support precise release modelling and batch-to-batch quality assurance, which are critical for regulatory approvals and clinician confidence.

Strategic collaborations are another defining feature, with manufacturers forming alliances across clinical research networks, contract manufacturers and specialty pharmacies to bolster route-to-market effectiveness. Companies that demonstrate excellence in clinician education and post-market support are better positioned to secure long-term contracts with health systems and large clinic networks. Additionally, firms that proactively generate real-world evidence and health economic data gain credibility in payer discussions, supporting adoption in environments where reimbursement decisions hinge on demonstrated cost-effectiveness and patient outcomes.

Supply chain robustness and diversification are increasingly important differentiators, particularly in light of recent trade policy shifts and component sourcing constraints. Organisations that maintain transparent and audit-ready supplier ecosystems, combined with contingency plans for critical inputs, achieve greater operational predictability. Finally, customer-centric commercial models that address procurement, clinician training and patient support holistically tend to outperform narrower transactional approaches, reinforcing the importance of integrated service offerings alongside device performance.

Clear, actionable directions for manufacturers and program leaders to accelerate adoption through material innovation, real-world evidence and resilient commercial models

Industry leaders seeking to strengthen their position should prioritise initiatives that reduce friction across clinical, regulatory and commercial pathways. First, investing in material science and formulation optimisation that simplifies insertion and removal procedures will improve clinician uptake and patient acceptance. By aligning product profiles with clear clinical differentiation-such as side-effect mitigation or simplified follow-up-manufacturers can shorten adoption curves.

Second, manufacturers should expand evidence-generation programs beyond pre-approval trials to include pragmatic, real-world studies that document long-term safety, patient satisfaction and health economic impact in diverse care settings. Such evidence supports payer discussions and procurement decisions, and it informs clinician education efforts. Third, strengthening supplier diversification and nearshoring where feasible will mitigate tariff exposure and logistical disruptions, while targeted automation investments can offset cost pressures without sacrificing quality.

Fourth, evolving commercial models to incorporate clinician training, digital adherence tools and coordinated distribution strategies through hospital pharmacies, online channels and retail networks will broaden access and reduce barriers to uptake. Finally, proactive engagement with public health stakeholders and programme implementers can create scalable deployment pathways in resource-constrained settings, enhancing both social impact and sustainable demand. These combined actions create a resilient, evidence-driven approach to growth and access.

A methodical research framework combining practitioner interviews, technical literature synthesis and scenario-based supply chain analysis to support actionable conclusions

The research approach underlying this executive summary combines a multi-dimensional evidence base and structured analytical methods to ensure robust, actionable conclusions. Primary qualitative inputs included in-depth interviews with clinicians, supply chain leads, regulatory experts and program implementers to capture practical insights about clinical workflows, insertion and removal practices, and procurement considerations. These practitioner perspectives were triangulated with regulatory guidance documents and published clinical literature to validate safety, tolerability and performance characteristics across device configurations.

Secondary research encompassed peer-reviewed scientific studies, materials science publications and device engineering reports to assess polymer behaviour and drug release mechanisms. Policy papers and health system analyses provided context on payer dynamics and public procurement approaches across regions. Synthesis of these sources focused on identifying recurring themes, inflection points and operational constraints rather than producing numerical market projections.

Analytical frameworks employed included segmentation analysis, value-chain mapping and scenario-based supply chain stress testing to evaluate risk exposure under varying tariff and sourcing conditions. Findings were iteratively reviewed with domain experts to ensure technical accuracy and relevance to practitioner decision-making. This methodology emphasises evidence integration, stakeholder validation and pragmatic recommendations aimed at supporting clinical, regulatory and commercial strategies.

A synthesis of technical, regulatory and operational trends underscoring the integrated priorities required for sustained clinical adoption and health system impact

The evolution of implantable contraceptive drug-eluting devices is being shaped by technical advances, shifting policy landscapes and operational pressures that together redefine strategic priorities for developers, manufacturers and healthcare providers. Material and formulation innovations are unlocking new device profiles while regulatory and payer expectations are increasing the need for real-world evidence and health economic justification. At the same time, trade policy and supply chain considerations are prompting organisations to reexamine sourcing strategies and operational resilience.

Successful market entrants will be those that integrate robust scientific platforms with agile manufacturing, evidence-led commercialization and collaborative public health engagement. By focusing on clinician usability, patient-centred outcomes and reliable supply channels, organisations can accelerate adoption while managing cost and regulatory risk. The interplay between device performance, service delivery and system-level value will continue to shape investment priorities and partnership models across regions. Ultimately, a coordinated approach that aligns technical excellence with operational and commercial preparedness will deliver the greatest impact for both patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Contraceptive Drug Eluting Devices Market, by Product Type

  • 8.1. Multi Rod
  • 8.2. Single Rod

9. Implantable Contraceptive Drug Eluting Devices Market, by Drug Type

  • 9.1. Etonogestrel
  • 9.2. Levonorgestrel

10. Implantable Contraceptive Drug Eluting Devices Market, by End User

  • 10.1. Clinics
    • 10.1.1. Private Clinics
    • 10.1.2. Public Clinics
  • 10.2. Family Planning Centers
  • 10.3. Hospitals

11. Implantable Contraceptive Drug Eluting Devices Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Implantable Contraceptive Drug Eluting Devices Market, by Polymer Material

  • 12.1. Biodegradable
  • 12.2. Non-Biodegradable

13. Implantable Contraceptive Drug Eluting Devices Market, by Duration

  • 13.1. Five Year
  • 13.2. Three Year

14. Implantable Contraceptive Drug Eluting Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Implantable Contraceptive Drug Eluting Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Implantable Contraceptive Drug Eluting Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Implantable Contraceptive Drug Eluting Devices Market

18. China Implantable Contraceptive Drug Eluting Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3Daughters, Inc.
  • 19.6. AbbVie Inc.
  • 19.7. Allergan, Inc.
  • 19.8. Bayer AG
  • 19.9. Boston Scientific Corporation
  • 19.10. Celanese Corporation
  • 19.11. Dare Bioscience, Inc.
  • 19.12. DKT International
  • 19.13. Femasys, Inc.
  • 19.14. Gedeon Richter Plc.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Lubrizol Life Science, Inc.
  • 19.17. Medicines360
  • 19.18. Medtronic plc
  • 19.19. Mithra Pharmaceuticals SA
  • 19.20. OCON Medical, Inc.
  • 19.21. Organon & Co.
  • 19.22. Pregna International Ltd.
  • 19.23. Shanghai Dahua Pharmaceutical Co., Ltd.
  • 19.24. The Cooper Companies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MULTI ROD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MULTI ROD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MULTI ROD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SINGLE ROD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SINGLE ROD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SINGLE ROD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETONOGESTREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETONOGESTREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETONOGESTREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY LEVONORGESTREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY LEVONORGESTREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PUBLIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PUBLIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FIVE YEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FIVE YEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FIVE YEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY THREE YEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY THREE YEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY THREE YEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 159. G7 IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. NATO IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA IMPLANTABLE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)